[{"data":1,"prerenderedAt":207},["ShallowReactive",2],{"drug-mannitol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":42,"contraindications":81,"warnings":91,"renal":99,"monitoring":100,"interactions":101,"review":102,"examples":105,"atc":120,"iran":122,"usApproval":154,"links":160,"populations":173},"mannitol",1,{"fa":7,"en":8},"مانیتول","Mannitol","blood",{"fa":11,"en":12},"دیورتیک اسموتیک","Osmotic diuretic",[14],{"name":15,"market":16},"Osmitrol","US",[18,7,19],"osmitrol","manitol",[21,34],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"bag-20","injection","iv","20% (0.2 g\u002FmL) 250\u002F500 mL bag",{"amount":27,"unit":28,"perVolumeMl":5},0.2,"g",[16],[31],{"source":32,"section":33},"fda-osmitrol","3",{"id":35,"form":23,"route":24,"label":36,"concentration":37,"markets":39,"refs":40},"bag-10","10% (0.1 g\u002FmL) 500 mL bag",{"amount":38,"unit":28,"perVolumeMl":5},0.1,[16],[41],{"source":32,"section":33},[43,67],{"id":44,"disease":45,"label":46,"population":49,"type":50,"unit":28,"dose":51,"refs":54,"durationDays":57,"notes":58},"icp","raised-intracranial-pressure",{"fa":47,"en":48},"کاهش فشار داخل جمجمه — ۰٫۲۵ g\u002Fkg وریدی طی ۳۰ دقیقه، هر ۶ تا ۸ ساعت در صورت نیاز","Reduce intracranial pressure — 0.25 g\u002Fkg IV over 30 min, repeat every 6–8 h",{},"weightBased",{"perKgPerDose":52,"intervalHours":53},0.25,24,[55],{"source":32,"section":56},"2.2",{"min":5,"max":5},[59],{"text":60,"refs":63},{"fa":61,"en":62},"ترجیحاً ورید مرکزی. پیش از شروع وضعیت کلیه، قلب و ریه و الکترولیت‌ها اصلاح؛ پایش اسمولالیته. با خون از یک ست نه.","Preferably a central vein. Assess renal, cardiac and pulmonary status and correct electrolytes first; monitor osmolality. Not with blood products in the same set.",[64,66],{"source":32,"section":65},"2.1",{"source":32,"section":56},{"id":68,"disease":69,"label":70,"population":73,"type":50,"unit":28,"dose":74,"refs":77,"durationDays":79,"allowedFormulations":80},"iop","glaucoma",{"fa":71,"en":72},"کاهش فشار داخل چشم — ۱٫۵ تا ۲ g\u002Fkg (محلول ۲۰٪) وریدی طی دست‌کم ۳۰ دقیقه، یک دوز","Reduce intraocular pressure — 1.5–2 g\u002Fkg (20% solution) IV over at least 30 min, single dose",{},{"perKgPerDose":75,"perKgPerDoseMax":76,"intervalHours":53},1.5,2,[78],{"source":32,"section":56},{"min":5,"max":5},[22],[82],{"id":83,"severity":84,"text":85,"refs":88},"ci","block",{"fa":86,"en":87},"حساسیت به مانیتول؛ آنوری؛ کمبود حجم شدید؛ احتقان یا ادم شدید ریه؛ خونریزی فعال داخل جمجمه (جز حین کرانیوتومی).","Hypersensitivity to mannitol; anuria; severe hypovolaemia; severe pulmonary congestion or oedema; active intracranial bleeding (except during craniotomy).",[89],{"source":32,"section":90},"4",[92],{"text":93,"refs":96},{"fa":94,"en":95},"نارسایی کلیه؛ سمیت CNS؛ اختلال آب و الکترولیت و هیپراسمولاریته؛ واکنش محل انفوزیون.","Renal failure; CNS toxicity; fluid\u002Felectrolyte imbalance and hyperosmolarity; infusion-site reactions.",[97],{"source":32,"section":98},"5",[],[],[],{"status":103,"reviewer":104,"date":104},"unverified",null,[106,113],{"regimen":44,"formulation":22,"input":107,"expect":110},{"ageYears":108,"weightKg":109},40,70,{"perDose":111,"mlPerDose":112},17.5,87.5,{"regimen":68,"formulation":22,"input":114,"expect":116},{"ageYears":115,"weightKg":109},60,{"perDose":117,"mlPerDose":118,"upperPerDose":119},105,525,140,[121],"B05BC01",{"status":123,"forms":124,"refs":149},"registered",[125,129,133,137,141,145],{"code":126,"en":127,"fa":128},"00781","MANNITOL 10% 0.5L INF","محلول انفوزیون مانیتول ۱۰ درصد ۰٫۵ لیتر",{"code":130,"en":131,"fa":132},"12328","MANNITOL 10% 1L INF","محلول انفوزیون مانیتول ۱۰ درصد ۱ لیتر",{"code":134,"en":135,"fa":136},"21599","MANNITOL 10% 250ML INF","محلول انفوزیون مانیتول ۱۰ درصد ۲۵۰ میلی‌لیتر",{"code":138,"en":139,"fa":140},"00782","MANNITOL 20% 0.5L INF","محلول انفوزیون مانیتول ۲۰ درصد ۰٫۵ لیتر",{"code":142,"en":143,"fa":144},"12327","MANNITOL 20% 1L INF","محلول انفوزیون مانیتول ۲۰ درصد ۱ لیتر",{"code":146,"en":147,"fa":148},"08804","MANNITOL 20% 250ML INF","محلول انفوزیون مانیتول ۲۰ درصد ۲۵۰ میلی‌لیتر",[150],{"source":151,"section":152,"url":153},"darooyab-generic","G-1747\u002FMannitol","https:\u002F\u002Fwww.darooyab.ir\u002FG-1747\u002FMannitol",{"kind":155,"refs":156,"id":159},"NDA",[157],{"source":32,"section":158},"SPL approval \u002F marketing category","NDA013684",[161,164,168,171],{"kind":162,"url":163,"label":159},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=013684",{"kind":165,"url":166,"label":167},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc","FDA Osmitrol",{"kind":169,"url":170,"label":121},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B05BC01",{"kind":172,"url":153,"label":8},"darooyab",{"pregnancy":174,"lactation":183,"pediatric":191,"geriatric":199},{"level":175,"text":176,"quote":179,"refs":180},"caution",{"fa":177,"en":178},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",[181],{"source":32,"section":182},"8.1",{"level":175,"text":184,"quote":187,"refs":188},{"fa":185,"en":186},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of mannitol in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.",[189],{"source":32,"section":190},"8.2",{"level":175,"text":192,"quote":195,"refs":196},{"fa":193,"en":194},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","OSMITROL is approved for use in the pediatric population for the reduction of intracranial and intraocular pressure.",[197],{"source":32,"section":198},"8.4",{"level":175,"text":200,"quote":203,"refs":204},{"fa":201,"en":202},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of OSMITROL [see Warnings and Precautions (5.2 , 5.3 , 5.4 , 5.5 )].",[205],{"source":32,"section":206},"8.5",1792444696473]